Biomarker overview

ALK fusion

Synonyms: ALK rearrangement|ALK+

Tumor-type contexts

Context map

Tumor type	Drug context	Role	Strategy	Context page
NSCLC	Therapy Not Normalized	Inclusion Required	Manual Review Required	Open
solid tumor basket	Combination Therapy	Inclusion Required	Trial Selection Rising	Open
NSCLC	Small Molecule Inhibitor	Inclusion Required	Manual Review Required	Open
solid tumor basket	Monoclonal Antibody	Inclusion Required	Drug Development Ahead Of Cdx Context	Open
breast cancer	Small Molecule Inhibitor	Inclusion Required	Manual Review Required	Open
melanoma	Combination Therapy	Secondary Or Exploratory	Exploratory Only Signal	Open
solid tumor basket	Therapy Not Normalized	Inclusion Required	Manual Review Required	Open
NSCLC	Immune Checkpoint Inhibitor	Inclusion Required	Cdx Established Context	Open
breast cancer	Immune Checkpoint Inhibitor	Inclusion Required	Trial Selection Rising	Open
melanoma	Small Molecule Inhibitor	Inclusion Required	Low Public Signal	Open
NSCLC	Combination Therapy	Inclusion Required	Cdx Established Context	Open
pancreatic cancer	Combination Therapy	Inclusion Required	Low Public Signal	Open
gastric cancer	Therapy Not Normalized	Inclusion Required	Trial Selection Rising	Open
gastric cancer	Small Molecule Inhibitor	Inclusion Required	Low Public Signal	Open
ovarian cancer	Combination Therapy	Inclusion Required	Trial Selection Rising	Open
colorectal cancer	Combination Therapy	Inclusion Required	Drug Development Ahead Of Cdx Context	Open
NSCLC	Monoclonal Antibody	Inclusion Required	Cdx Established Context	Open
solid tumor basket	Small Molecule Inhibitor	Inclusion Required	Trial Selection Rising	Open
solid tumor basket	Immune Checkpoint Inhibitor	Inclusion Required	Trial Selection Rising	Open
pancreatic cancer	Small Molecule Inhibitor	Inclusion Required	Low Public Signal	Open
breast cancer	Therapy Not Normalized	Inclusion Required	Manual Review Required	Open
melanoma	Immune Checkpoint Inhibitor	Inclusion Required	Low Public Signal	Open
breast cancer	Monoclonal Antibody	Inclusion Required	Drug Development Ahead Of Cdx Context	Open
ovarian cancer	Small Molecule Inhibitor	Inclusion Required	Low Public Signal	Open
ovarian cancer	Therapy Not Normalized	Inclusion Required	Trial Selection Rising	Open
breast cancer	Combination Therapy	Inclusion Required	Trial Selection Rising	Open
colorectal cancer	Small Molecule Inhibitor	Inclusion Required	Manual Review Required	Open
pancreatic cancer	Monoclonal Antibody	Inclusion Required	Low Public Signal	Open
colorectal cancer	Therapy Not Normalized	Inclusion Required	Drug Development Ahead Of Cdx Context	Open
melanoma	Therapy Not Normalized	Resistance Subgroup	Low Public Signal	Open
NSCLC	ADC	Inclusion Required	Cdx Established Context	Open
gastric cancer	Monoclonal Antibody	Inclusion Required	Drug Development Ahead Of Cdx Context	Open
ovarian cancer	Immune Checkpoint Inhibitor	Inclusion Required	Low Public Signal	Open
melanoma	Monoclonal Antibody	Inclusion Required	Low Public Signal	Open
gastric cancer	Combination Therapy	Inclusion Required	Trial Selection Rising	Open
colorectal cancer	Immune Checkpoint Inhibitor	Inclusion Required	Trial Selection Rising	Open
gastric cancer	Immune Checkpoint Inhibitor	Inclusion Required	Low Public Signal	Open